“2025 was a transformational year for ORIC highlighted by clinical data that further demonstrated the potential best-in-class profiles of rinzimetostat in prostate cancer and enozertinib in lung cancer,” said Jacob M. Chacko, M.D., president and chief executive officer. “Those data, along with substantially extended cash runway, position us well for 2026 and beyond as we advance our programs towards registrational studies.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Piper Sandler Puts its Weight Behind 2 ‘Strong Buy’ Cancer Stocks
- ORIC Pharmaceuticals: Dense Near‑Term Clinical Catalysts and Encouraging Efficacy Data Underpin Reiterated Buy Rating
- Oric Pharmaceuticals provides operational highlights for 2025
- 3 Best Biotech Stocks to Buy Today, 1/7/2026, According to Top Analysts
- Oric Pharmaceuticals initiated with an Overweight at Piper Sandler